

BioMarin to Present at the Leerink Swann & Company/MEDACorp Hypertension Roundtable Conference

PRNewswire-FirstCall

NOVATO, Calif.

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Leerink Swann & Company/MEDACorp Conference, Vascular Modulation ... New Strategies for Treating Major Forms of Hypertension (Acute, Resistant and Pulmonary) Roundtable, in Boston on Friday, April 28, 2006 at 2:30 p.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Additionally, BioMarin has rights to receive payments and royalties related to Orapred(R) (prednisolone sodium phosphate oral solution). Investigational product candidates include

Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU).

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

NOTE: Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

Contacts:

Investors

Joshua A. Grass
BioMarin Pharmaceutical Inc.
415-506-6777

Media

Susan Ferris
BioMarin Pharmaceutical Inc.
415-506-6701

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: investors, Joshua A. Grass, +1-415-506-6777, or media, Susan Ferris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.

Web site: <http://www.bmrn.com/>

<https://investors.biomin.com/2006-04-20-BioMarin-to-Present-at-the-Leerink-Swann-Company-MEDACorp-Hypertension-Roundtable-Conference>